Cargando…
Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incide...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213903/ https://www.ncbi.nlm.nih.gov/pubmed/34179534 http://dx.doi.org/10.1016/j.heliyon.2021.e07260 |
_version_ | 1783709950870028288 |
---|---|
author | Mirahmadizadeh, Alireza Banihashemi, Sayed Aliakbar Hashemi, Mehdi Amiri, Sanaz Basir, Suzan Heiran, Alireza Keshavarzian, Omid |
author_facet | Mirahmadizadeh, Alireza Banihashemi, Sayed Aliakbar Hashemi, Mehdi Amiri, Sanaz Basir, Suzan Heiran, Alireza Keshavarzian, Omid |
author_sort | Mirahmadizadeh, Alireza |
collection | PubMed |
description | AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incidence of type 2 diabetes in Fars province, Iran, using prescription data and a stepwise approach to ascertain the results. METHODS: A dataset of 3,113 insured individuals aged ≥35 years were selected. Their Prescription Data Centre records were reviewed for all drugs frequently used in controlling type 2 diabetes available in the Iranian pharmacopeia. Then we used a stepwise method for case-finding. In step one, each individual with a positive drug history for type 2 diabetes was labeled as an individual with diabetes. The next two steps were implemented for ascertainment of step one estimations. RESULTS: Prevalence of type 2 diabetes based on prescription, internist opinion, and phone call verification in 2015 and 2016 was 9.3% and 10.3%, 8.5% and 9.8%, and 7.2% and 8.7%, respectively. An incidence of 1.9% was determined for 2016. CONCLUSIONS: We obtained a realistic estimation of prevalence and incidence of treated type 2 diabetes, using prescription data which are large-scale, low cost, and real-time. |
format | Online Article Text |
id | pubmed-8213903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82139032021-06-25 Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data Mirahmadizadeh, Alireza Banihashemi, Sayed Aliakbar Hashemi, Mehdi Amiri, Sanaz Basir, Suzan Heiran, Alireza Keshavarzian, Omid Heliyon Research Article AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incidence of type 2 diabetes in Fars province, Iran, using prescription data and a stepwise approach to ascertain the results. METHODS: A dataset of 3,113 insured individuals aged ≥35 years were selected. Their Prescription Data Centre records were reviewed for all drugs frequently used in controlling type 2 diabetes available in the Iranian pharmacopeia. Then we used a stepwise method for case-finding. In step one, each individual with a positive drug history for type 2 diabetes was labeled as an individual with diabetes. The next two steps were implemented for ascertainment of step one estimations. RESULTS: Prevalence of type 2 diabetes based on prescription, internist opinion, and phone call verification in 2015 and 2016 was 9.3% and 10.3%, 8.5% and 9.8%, and 7.2% and 8.7%, respectively. An incidence of 1.9% was determined for 2016. CONCLUSIONS: We obtained a realistic estimation of prevalence and incidence of treated type 2 diabetes, using prescription data which are large-scale, low cost, and real-time. Elsevier 2021-06-09 /pmc/articles/PMC8213903/ /pubmed/34179534 http://dx.doi.org/10.1016/j.heliyon.2021.e07260 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Mirahmadizadeh, Alireza Banihashemi, Sayed Aliakbar Hashemi, Mehdi Amiri, Sanaz Basir, Suzan Heiran, Alireza Keshavarzian, Omid Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title | Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title_full | Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title_fullStr | Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title_full_unstemmed | Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title_short | Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data |
title_sort | estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: a stepwise approach on iranian data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213903/ https://www.ncbi.nlm.nih.gov/pubmed/34179534 http://dx.doi.org/10.1016/j.heliyon.2021.e07260 |
work_keys_str_mv | AT mirahmadizadehalireza estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT banihashemisayedaliakbar estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT hashemimehdi estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT amirisanaz estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT basirsuzan estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT heiranalireza estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata AT keshavarzianomid estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata |